Completed PHASE3 INTERVENTIONAL 2-arm NCT02101359

Efficacy and Safety Assessment of Intracameral Injection of T2380 in Cataract Surgery

Efficacy and Safety Assessment of Intracameral Injection of T2380 in Cataract Surgery Versus Reference Group (Topical Mydriatics and Anaesthetic)

Sponsor: Laboratoires Thea

Conditions Cataract

Interventions Mydriatics T2380 Tetracaine

Updated 6 times since 2017 Last updated: Nov 4, 2014 Started: Jun 30, 2011 Primary completion: Jan 31, 2013 Completion: May 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Cataract and is currently completed. Laboratoires Thea leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Laboratoires Thea

Data source: Laboratoires Thea

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Clermont-Ferrand, France